



Received on 09 December 2020; received in revised form, 09 May 2021; accepted, 29 May 2021; published 01 January 2022

## CAUSES, DIAGNOSIS AND MANAGEMENT OF MALE INFERTILITY: PHYTOCOMPOUNDS AS NATURAL SERMs- A REVIEW

Nithya Sethumadhavan

Department of Biotechnology, Biochemistry and Bioinformatics, Avinashilingam Institute of Home Science and Higher Education for Women, Bharathi park road, Tatabad, Forest College Campus, Saibaba Colony, Coimbatore – 641043, Tamil Nadu, India.

### Keywords:

Infertility, Idiopathic male Infertility, Phytochemicals, SERMs, Natural SERMs

### Correspondence to Author:

**Nithya Sethumadhavan**

Department of Biotechnology, Biochemistry and Bioinformatics, Avinashilingam Institute of Home Science and Higher Education for Women, Bharathi park road, Tatabad, Forest college campus, Saibaba colony, Coimbatore- 641043, Tamil Nadu, India.

**E-mail:** nithyasivaraaman@gmail.com

**ABSTRACT:** Infertility is an inability to achieve pregnancy in spite of regular, unprotected coitus in one year. Infertility affects about 15% of couples, in which the malefactor contributes to 40% worldwide. There are various risk factors, causes, and treatment modalities for male infertility, of which Selective Estrogen receptor modulators (SERMs) are one of the promising treatments available for treating idiopathic male Infertility. Idiopathic male Infertility refers to an abnormality in semen parameters without an identifiable cause and diagnosis recently known. SERMs are structurally diverse non-steroidal compounds which bind to estrogen receptor (ER) to exert tissue-specific estrogen agonist and antagonist effects. Several compounds, including clomiphene, tamoxifen, toremifene are currently available synthetic SERMs of which clomiphene & tamoxifen are commonly used in treating idiopathic male Infertility. While these compounds are effective in treating male infertility, their long-term use increases the risk of stroke, cataract, vision-threatening ocular toxicity, deep vein thrombosis, pulmonary embolism, and even more. The aim of this review is to highlight the causes, diagnosis & management of male fertility and to reveal the unforeseen effect of long-term use of SERMs. Also, this article will review the safe use of phytochemicals as natural SERMs.

**INTRODUCTION:** Infertility rates have dramatically increased in the last two decades, especially in men. It has been reported that environmental factors and lifestyle habits affect semen quality. Among males, the commonest cause of Infertility is Azoospermia (semen contains no sperm) and Oligozoospermia (Semen contains very few sperm), resulting from various pretesticular, testicular, and posttesticular causes.

Idiopathic male infertility refers to abnormal semen analysis without etiological factors identifiable from history, physical examination, or endocrine factors.

Many agents are being used to treat male infertility, of which SERMs are Non-Steroidal compounds that act as tissues specific Estrogen receptor agonists or Antagonists. The Anti estrogenic activity of SERMs on hypothalamus increases gonadotropins with a significant increase in testosterone while maintaining the spermatogenesis. Among SERMs, Clomiphene and Tamoxifen have successfully been used for decades to treat idiopathic Oligozoospermia and Azoospermia. Though the efficacy of SERMs to induce spermatogenesis is proven, the long term

<p><b>QUICK RESPONSE CODE</b></p> 	<p><b>DOI:</b> 10.13040/IJPSR.0975-8232.13(1).130-38</p>
<p>This article can be accessed online on <a href="http://www.ijpsr.com">www.ijpsr.com</a></p>	
<p>DOI link: <a href="http://dx.doi.org/10.13040/IJPSR.0975-8232.13(1).130-38">http://dx.doi.org/10.13040/IJPSR.0975-8232.13(1).130-38</a></p>	

use of SERMs is questionable with no proof for safety and have been associated with an increase in risk for cataract, pulmonary embolism, Deep Vein Thrombosis, Stroke, Vision threatening ocular toxicity, *etc.* Because of these long term effects of synthetic SERMs, there is a growing interest in the pharmacological evaluation of phytochemicals as natural SERMs

## 2. Literature Review:

**A. Defining Infertility:** Infertility is the inability of a sexually active couple to achieve clinical pregnancy in 1 year of unprotected coitus (WHO) <sup>1</sup>.

The incidence of infertility has increased worldwide in the last three decades, were 60-80 million couples worldwide and 15-20 million are in India alone <sup>2</sup>.

Infertility is a gynaecological problem affecting about 15% of couples attempting for 1st pregnancy (Primary Infertility) and 10% of the couple trying for subsequent pregnancy (Secondary Infertility) <sup>3</sup>.

There are various tools to study the fertility status of the male. Semen analysis is the basic and single most useful investigations to assess male infertility with 89.6% sensitivity <sup>4</sup>.

This simple test provides an insight into sperm count, motility, morphology, and other immunological factors as well <sup>5</sup>.

Male Infertility can be possibly due to (According to WHO 2010 criteria)

- Azoospermia (no spermin the ejaculate)
- Oligozoospermia (reduced sperm count)
- Asthenozoospermia (reduced sperm motility)
- Teratozoospermia (reduced sperm morphology)
- Necrozoospermia (reduced vitality) or combinations of these.

Various pre-testicular, testicular or post-testicular factors affect semen parameters <sup>6</sup>. Another group is idiopathic male Infertility, where the cause of infertility is unknown.

**B. Causes, Diagnosis and Management of Male Infertility:** This article presents an overview of the causes, evaluation and management of male infertility.

**2.1 Testicular Deficiency:** Testicular deficiency can be caused by either of the three

1. Congenital abnormalities including Anorchia, Cryptorchidism, testicular dysgenesis and Genetic abnormalities.
2. Acquired due to trauma, post-inflammatory like mump orchitis, exogenous factors like medication, and testicular torsion.
3. Systematic diseases including varicocele, testicular atrophy, testicular tumour
4. Primary testicular deficiency of unknown aetiology.

Evaluation of primary testicular failure from history and physical examination would reveal unilateral or bilateral cryptorchidism, testicular torsion/trauma, UTI, exposure to radiation, testicular cancer, absence of testes, absence of secondary sexual characters, gynecomastia, abnormal testicular volume and or consistency or varicocele.

In the case of testicular deficiency, semen analysis shows no sperm after centrifugation at 3000g for 10 Minutes <sup>7</sup>. USG Scrotum with doppler would reveal conditions like rete testis, enlarged epididymis with cystic lesions or absent vas deference, testicular dysgenesis or testis tumour<sup>8</sup>. Endocrine Factors shows an increased Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) with or without a decrease in Testosterone (T) <sup>9, 10</sup>. Testicular biopsy can be considered as a part of ICSI if viable sperm could be retrieved.

**2.2 Genetic Disorders:** The incidence of chromosomal abnormality is 5.8% <sup>11</sup>. Genetic disorders on infertility can be confirmed by screening genomic DNA from peripheral blood. Chromosomal abnormalities can be numerical or structural. The frequency of chromosomal abnormality increases with an increase in testicular deficiency and is ten folds higher in patients with sperm count <5 m/ml <sup>12, 13</sup>.

Klinefelter syndrome of the most common sex chromosome abnormality<sup>14</sup>. Adults with Klinefelter syndrome have relatively small testis without germ cells and other characteristics, including scanty body hair, long arm, and legs, female hair distribution<sup>15</sup>. The endocrine evaluation shows a normal or decreased T, normal or increased Estradiol (E2), and increased FSH. PGD/amniocentesis should be considered when IVF or ICSI is planned for men with translocation<sup>16,17</sup>.

Management of genetic disorders, including androgen replacement therapy in patients with hypo-androgenism, would be beneficial in maintaining general health too<sup>18</sup>.

In X Linked Genetic Disorders, the defect will be transmitted to daughters and not sons. Some of the X Linked disorders include but not restricted to

1. Kallmann's syndrome a condition where patients have hypogonadotropic hypogonadism and features like cleft palate, facial asymmetry, colour blindness, deafness, and maldescended / undescended testes, which is due to a mutation in the kalig1 gene on X Chromosome<sup>19, 20</sup>. In this case, hormonal treatment can be the best choice to induce spermatogenesis.

2. Mild Androgen insensitivity syndrome is a condition where there is a mutation in the AR gene located on the long arm of the X chromosome. Phenotype ranges from Morris syndrome, Reifferrstein syndrome. The risk of transmission is nearly negligible since the affected male cannot have their biological children<sup>21, 22, 23, 24</sup>.

**Y Chromosome and Infertility** Microdeletions in the Y chromosome are one of the commonest and frequent causes of severe oligozoospermia and Azoospermia<sup>25</sup>. The Highest frequency is found in 8-12% of azoospermic male, followed by 3-7% in oligozoospermic men. Since Y microdeletions can be transmitted to male children where offspring can develop turner's syndrome with chromosome mosaicism and ambiguous genitalia<sup>26</sup> where genetic counselling plays a major role.

**2.3 Cystic Fibrosis:** Cystic fibrosis is a fatal autosomal recessive disorder caused by a mutation in chromosome 7 P, which encodes a membrane

protein that influences the formation of the distal two-thirds of the epididymis, seminal vesicle, ejaculatory duct, vas deference. One of the complications of mutation in the gene 7P is Azoospermia due to congenital absence of bilateral vas deference, where ICSI can be considered.

**2.4 Obstructive Azoospermia:** It refers to the absence of sperm and spermatogenic cells in the ejaculate due to obstruction. In this condition, endocrine factors show normal FSH. Physical examination reveals normal testes with epididymal enlargement. Obstruction can be in either of the listed including:

1. Congenital Intratesticular obstruction in 15% men<sup>27</sup> or acquired (post-traumatic or inflammatory)
2. Epididymal obstruction affects 30 to 67% of azoospermic men<sup>28</sup>. It can be congenital (young's syndrome) or acquired (secondary to gonococcal infection) or epididymitis or trauma<sup>29, 30</sup>.
3. Obstruction in vas can be congenital due to Congenital Bilateral Absence of Vas Deferens (CBAVD) or agenesis or acquired post hernia repair or vasectomy reversal<sup>31</sup>.
4. Ejaculatory duct obstruction in 1 to 3% of oligoasthenozoospermia can be congenital due to cyst in Mullerian duct or urogenital sinus or Acquired post-surgical or post inflammation<sup>32</sup>, which decreases semen volume with decreased or absent fructose and acidic PH.

In obstructive Azoospermia, clinical examination reveals dilated epididymis with nodules in epididymis or vas, partial atresia, or absence of vas deferens. Confirmatory tests for obstructive oligo as then ozoospermiainclude semen analysis having very few or no sperm in the ejaculate, normal FSH, and inhibin B. Testicular biopsy should be performed to exclude testicular causes.

Obstructive Azoospermia can be managed by MESA (Microsurgical epididymal sperm aspiration) in men with CBAVD, Testicular Sperm Extraction (TESE) in case of Intratesticular obstruction, vasovasostomy in proximal vas Obstruction, microsurgical tabulovasostomy, Testicular Sperm Aspiration (TESA) or MESA or proximal vas deferens sperm aspiration in distal vas

obstruction<sup>33</sup>, Trans Urethral Resection Of Ejaculatory Ducts (TURED) in case of large post-inflammatory ejaculatory duct obstruction followed by ICSI. MESA/TESA can also be an alternative to TURED.

**2.5 Varicocele:** Varicocele is one of the conditions for male subfertility. Most of the times, varicocele can be diagnosed by clinical examination and can be confirmed by USG and graded as Sub Clinical (shown by USG Doppler but not palpable), Grade 1 (Palpable during Valsalvamanoeuvre), Grade 2 (Palpable at rest), Grade 3 (Visible and palpable at rest)

Microsurgical varicocelectomy would improve semen parameters in men with non-obstructive Azoospermia caused by varicocele.

**2.6 Hypogonadism:** Hypogonadism is one of the causes of the impaired testicular function which affects spermatogenesis and or steroidogenesis.

Male hypogonadism can be:

1. Primary due to hyper gonadotropic hypogonadism as a result of testicular failure.
2. Secondary hyper gonadotropic hypogonadism as a result of insufficient Gonadotropin-releasing Hormone (GnRH) and or FSH, LH.
3. Endorgan resistance.
4. Idiopathic hyper gonadotropic hypogonadism characterized by a low level of FSH, LH, and normal hypothalamic-pituitary-gonadal axis<sup>34</sup>.

In case of hypogonadotropic, hypogonadism of hypothalamic origin spermatogenesis can be induced by treatment with Human Chorionic Gonadotropin (HCG), Recombinant FSH(rFSH), Human Menopausal Gonadotropin(HMG)<sup>35, 36</sup> or pulsatile GnRH<sup>37</sup> Anti-estrogen and aromatase inhibitors may help in treating hyper gonadotropic hypogonadism<sup>38</sup>.

**2.7 Cryptorchidism:** Cryptorchidism is a most common congenital abnormality and is so-called testicular dysgenesis. 42% of patients with cryptorchidism are azoospermic, and 31% are Oligozoospermic. Surgical treatment followed by

GnRH therapy would be beneficial in managing infertility due to cryptorchidism.

**2.8 Idiopathic Male Infertility:** About 44% of patients suffer from Idiopathic Male Infertility, where the cause for infertility is unknown. A number of molecules have successfully been used as empirical treatment for idiopathic male Infertility, including gonadotropins (HMG/rFSH/HPFSH)<sup>39, 40</sup> with oral antioxidant. SERMs have long been used as a successful treatment modality for idiopathic male Infertility.

**3. SERMS:** SERMs are non-steroidal compounds that function as ligands for Estrogen receptors and acts as either estrogen agonists or antagonists depending on specific target tissue<sup>41</sup>.

SERMs have long been used as a promising treatment to treat idiopathic male Infertility. At present clomiphene and tamoxifen are the most commonly used SERMs. These compounds block negative feedback at the hypothalamus and pituitary level, thus increasing FSH, LH from anterior pituitary, which further increases T and thus aiding spermatogenesis.

The selective effect of SERMs are as a result of differential expression of ER(Estrogen Receptor) genes, *i.e.* ER $\alpha$  and  $\beta$ . ER $\alpha$  and  $\beta$  exert a different effect on the growth and differentiation of tissue including the uterus, liver, bone, colon, brain, mammary gland, testes *etc.*<sup>42, 43, 44, 45, 46, 47, 48</sup>.

In testes, both ER $\alpha$  and  $\beta$  have different cellular expression, ER $\alpha$  in nuclei of Leydig cells, while ER $\beta$  in germ cells, Sertoli cells and fetal Leydig cells<sup>49, 50</sup>.

According to a study, tamoxifen administration led to a two-fold increase in sperm concentration. Based on various studies, tamoxifen has been proposed by WHO as the first-line treatment for idiopathic oligozoospermia<sup>51</sup>.

A study from India conducted on 25 men with severe oligozoospermia had an increase in sperm count from 3 M/ml to 8.2 M/ml after three months of clomiphene therapy, and in the same study 40 men with oligozoospermia had an increase in counts from 13 M/ml to 24 M/ml<sup>52</sup>.



A study on 183 patients grouped into tamoxifen only, tamoxifen and COQ 10 and COQ 10 showed an increase in motility and morphology in tamoxifen and COQ 10 and COQ 10 but not in tamoxifen only<sup>53</sup>.

From the above studies, though it is proved that SERMs are best suited for empiric treatment of idiopathic male Infertility, some side effects have been reported on long-term use, including headache, nausea, pulmonary embolism, palpitation, seizure *etc.* Since there is no long-term safety data on these medications, the research on pharmacological effects of phytochemicals on SERMs is of greater interest in recent days.

The most common adverse effect is generally reversible visual disturbances in less than 2 % of patients due to vascular sludging leading to ischemic optic neuropathy. High dose of tamoxifen is a hepato-carcinogen in rats and have been shown to induce cataracts in rats. In osteoporotic women, the comparative risk for DVT & pulmonary embolism was 3.1 times higher than placebo. Retinopathy has been reported in patients on high doses of tamoxifen; vision-threatening ocular toxicity has been rarely observed. Other common adverse effects include nausea, dizziness, oedema, vomiting, development of corneal opacification *etc.*

**4. Medicinal Plants on Male Infertility:** Medicinal plants have been the basis of treatment for a long period in Asian and African folk medicine. They are the natural resources of modern medicine since they are the potential source of phytochemical compounds like steroids, terpenoids, glycosides, glycoprotein, proteins, alkaloids, flavonoids, *etc.*<sup>54</sup>

There is emerging information regarding phytoestrogens that can be regarded as natural SERMs which possess antiestrogenic activities, including isoflavones like genistein, daidzein, flavones like coumestans, lignans, mycoestrogens such as zearalenone, *etc.*

Medicinal plants can be used as an extensive source to treat various diseases<sup>55</sup>. Phytochemicals have vastly been studied for their antioxidant, antitumor, immunomodulatory, antimicrobial properties<sup>56</sup>. Many plants have been studied for their male fertility-enhancing properties.

*Eurycoma longifolia* jack referred to as Tongkat, a native of East Asia has found to be rich in various phytochemicals and have been indicated for a wide range of activities such as antimalarial, anticancer and antibacterial besides treating male Infertility<sup>57</sup>.

The effect of ethanolic extract was studied on both androgenic and proliferative activity and was found to overcome the late-onset of hypogonadism by biosynthesis of various androgens<sup>58</sup>.



**FIG. 1: EURYCOMA LONGIFOLIA**

*Cardiospermum halicacabum* is a popular herb of Sri Lanka commonly referred to as balloon vine.

Various doses (200, 400 and 800 mg/kg, twice daily for ten days) have found to increase caput and epididymal sperm count in rats due to its rich phytochemicals especially flavonoids<sup>59</sup>.



**FIG. 2: CARDIOSPERMUM HALICACABUM**



**FIG. 3: GRAPESEED**

Grape seed extract has shown to increase semen parameters including sperm count, viability and motility in a study on aluminium chloride-induced testicular dysfunction in rats and has been reported to reduce the germ cell apoptosis induced by testicular torsion<sup>60</sup>.

*Syzygium aromaticum*, a native of Indonesia, commonly referred to as clove, has traditionally been used as a cure for sexual dysfunction and libido<sup>61</sup>.



**FIG. 4: SYZYGIIUM AROMATICUM**

streptozotocin-induced diabetic rats were treated with 0.5 ml/day for two months with *Nigella sativa*, which are rich in more than a hundred phyto-compounds and has shown to increase testosterone<sup>62</sup>.



**FIG. 5: NIGELLA SATIVA**



**FIG. 6: LYCIUM BARBARUM**

Normal and hemicastrated rats were treated for 14 and 21 days with 10 mg/kg of *Lycium barbarum* a Chinese herb that has long been used as an

aphrodisiac and has proved to attenuate the testicular DNA damage and also by increasing testosterone<sup>63</sup>.

*Tribulus terrestris*, a perennial creeping herb, has been identified as a cure for treating male Infertility In Asia and Europe. A study of *Tribulus terrestris* on sodium valproate treated male rats showed a dose-dependent increase in the level of testosterone, FSH, and LH<sup>64</sup>.



**FIG. 7: TRIBULUS TERRESTIS**

*Asteracantha longifolia* have potentially been used as an aphrodisiac and androgenic agent for centuries. Ethanolic extract of *Polycarpea corymbosa* a local herb of Tamil Nadu increased the level of T and LH<sup>65</sup>.



**FIG. 8: ASTERACANTHA LONGIFOLIA**



**FIG. 9: POLYCARPEA CORYMBOSA**

A study conducted on mouse Leydig cells reported the steroidogenic effect of *Taraxacum officinale* to extract<sup>66</sup>.





FIG. 10: *TARAXACUM OFFICINALE*

*Rosa damascena*, an ancient holy herb, was studied for its androgenic effect on male Wistar rats. 400 mg/kg of the extract for 21 days was found to increase FSH, LH and T<sup>67</sup>.



FIG. 11: *ROSA DAMASCENA*

**CONCLUSION:** Infertility is a condition which results in stress, trauma and drastic effect with a strong emphasis on childbearing. There are various causes and risk factors for male infertility, including but not limited to environmental and lifestyle factors.

Knowledge regarding male infertility is very limited, and most of the treatments for male infertility are long-term with an ineffective and also undesirable outcome, as mentioned.

There are studies that show the antiestrogenic effect of SERMs, which increase gonadotrophin level and, therefore a significant increase in testosterone while maintaining spermatogenesis. Although SERMs are effective for treating male infertility, long-term use of SERMs increases the risk on general health.

Because of these long-term effects of synthetic SERMs, greater research focuses on the use of phyto-compounds as natural SERMs. Many plant-based compounds have been reviewed in this article for their effectiveness in enhancing male fertility.

**ACKNOWLEDGEMENT:** I thank Dr. Kalyana Kumari, Advanced Endogynaec Surgeon, Royalcare Super Speciality Hospital, for her support. I am grateful to Mr. Arun and Mr. Anirudha for their help in proofreading the manuscript.

**CONFLICTS OF INTEREST:** The authors declare there is no conflict of interest.

#### REFERENCES:

1. WHO manual for the standardized Investigation and diagnosis of Infertile couple. Cambridge University Press, 2000, Cambridge.
2. Anju M, Katiyar DK, Anju A, Vineeta D and Pant KK: Role of total antioxidant capacity and lipid peroxidation in fertile and infertile men. Biomed Research 2013; 24 (3): 347-52.
3. Jimoh AAG, Olawuyi TS, Omotoso GO, Oyewopo AO and Dare JK: Semen parameters and hormone profile of men investigated for infertility at midland fertility centre, Ilorin, Nigeria. JBasic ApplSci 2010; 8: 110-13.
4. Butt F and Akram N: Semen analysis parameters: experiences and insight into male infertility at a tertiary care hospital in Punjab. J Pak Med Assoc 2013; 63(5): 558-62.
5. Fisch H: Declining worldwide sperm counts: disproving a myth. Urol Clin North Am 2008; 35(2): 137-46.
6. Kumar N and Singh AK: Trends of male factor infertility, an important cause of Infertility: A review of the literature. J Hum Reprod Sci 2015; 8(4): 191-96.
7. WHO, WHO Laboratory manual for the Examination and Processing of Human Semen. 2010 5th edition.
8. Lotti F and Maggi M: Ultrasound of the male genital tract in relation to male reproductive health. Hum Reprod Update 2015; 21(1): 56-83.
9. Ron MD, Peter D, Smith T, Southwick GJ and Kretser D: Fertility in cases of hypergonadotropic Azoospermia. Fertil steril 1995; 63(3): 631-36.
10. Pan RC and Bischof P: Increased follicle-stimulating hormone in infertile men. Is increased plasma FSH always due to damaged germinal epithelium?. Hum Reprod 1995; 10(8): 1940-45.
11. Johnson MD: Genetic risks of intracytoplasmic sperm injection in the treatment of male infertility: recommendations for genetic counselling and screening. Fertil Steril 1998; 70(3): 397-11.
12. Clementini E, Palka C, Iezzi I, Stuppia L, GuancialiFranchi P and Tiboni GM: Prevalence of chromosomal abnormalities in 2078 infertile couples referred for assisted reproductive techniques. Hum Reprod 2005; 20(2): 437-42.
13. Vincent MC, Daudin M, De MP, Massat G, Mieusset R and Pontonnier F: Cytogenetic investigations of infertile men with low sperm counts: a 25-year experience. J Androl 2002; 23(1): 18-22.
14. Garza SA and Patrizio P: Reproductive outcomes in patients with male infertility because of Klinefelter's syndrome, Kartagener's syndrome, round-head sperm, dysplasia fibrous sheath, and 'stump' tail sperm: an updated literature review. Curr Opin Obstet Gynecol 2013; 25(3): 229-46.

15. Wang C, Baker HWG, Krester DM and Hudson B: Hormonal Studies in Klinefelter's syndrome. *Clin Endocrinol* 1975; 4(4): 399-11.
16. Nguyen MH, Morel F, Pennamen P, Parent P, Guilbert N and Bris MJ: Balanced, complex chromosome rearrangement in male infertility: case report and literature review. *Andrologia* 2014; 47 (2): 178-85.
17. Siffroi JP, Benzacken B, Straub B, Bourhis C, North MO and Curotti G: Assisted reproductive technology and complex chromosomal rearrangements: the limits of ICSI. *Mol Hum Reprod* 1997; 3(10): 847-51.
18. Groth KA, Skakkebak A, Host C, Gravholt CH and Bojesen A: Clinical review: Klinefelter syndrome--a clinical update. *J Clin Endocrinol Metab* 2013; 98(1): 2012-82.
19. Tempest H and Martin R: Cytogenetic risks in chromosomally normal infertile men. *Curr Opin Obstet Gyn* 2009; 21(3): 223-27.
20. Baccetti B, Collodel G, Marzella R, Moretti E, Piomboni P and Scapigliati G: Ultrastructural studies of spermatozoa from infertile males with Robertsonian translocations and 18, X, Y aneuploidies. *Hum Reprod* 2005; 20(8): 2295-00.
21. Ferlin A, Vinanzi C, Garolla A, Selice R, Zuccarello D and Cazzadore C: Male infertility and androgen receptor gene mutations: clinical features and identification of seven novel mutations. *Clin Endocrinol* 2006; 65(5): 606-10.
22. Gottlieb B, Lombroso R, Beitel LK and Trifiro MA: Molecular pathology of the androgen receptor in male (in) fertility. *Reprod Biomed Online* 2005; 10(1): 42-48.
23. Rajender S, Singh L and Thangaraj K: Phenotypic heterogeneity of mutations in the androgen receptor gene. *Asian J Androl* 2007; 9(2): 147-79.
24. Tincello DG, Saunders PTK and Hargreave TB: Preliminary investigations on androgen receptor gene mutations in infertile men. *MolHumReprod*1997; 3(11): 941-943.
25. Krausz C and Casamonti E: Spermatogenic failure and the Y chromosome. *Human Genet* 2017; 136(5): 637-55.
26. Patsalis PC, Sismani C, Murci L, Bekkouche F, Krausz C and Elreavey K: Effects of transmission of Y chromosome AZFc deletions. *Lancet* 2002; 360(9341): 1222-24.
27. Hendry W: Azoospermia and surgery for testicular obstruction. In Hargreave TB, *Male Infertility*. Springer Verlag: Berlin 1997.
28. Hendry WF, Parslow JM and Stedronska J: Exploratory Scrototomy in 168 Azoospermic Males. *Br J Urol* 1983; 55(6): 785-91.
29. Jarvi K, Zini A, Buckspan MB, Asch M, Ginzburg B and Margolis M: Adverse effects on vasoepididymostomy outcomes for men with concomitant abnormalities in the prostate and seminal vesicle. *J Urol* 1998; 160(4): 1410-2.
30. Matthews GJ, Schlegel PN and Goldstein M: Patency following microsurgical vasoepididymostomy and vasovasostomy: temporal considerations *J Urol* 1995; 154(6): 2070-73.
31. Schoysman R: Vaso-epididymostomy-a survey of techniques and results with considerations of delay of appearance of spermatozoa after surgery. *Acta Eur Fert* 1990; 21(5): 239-45.
32. Printzen IM, Ludwig M, Köhn F and Weidner W: Surgical therapy in infertile men with ejaculatory duct obstruction: technique and outcome of a standardized surgical approach. *Hum Reprod* 2000; 15(6): 1364-68.
33. Sarquella J, Pomerol MD and Romero J: A new device for microsurgical Sperm aspiration. *Andrologia* 1994; 26(2): 119-20.
34. Bianco SD and Kaiser UB: The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. *Nat Rev Endocrinol* 2009; 5(10): 569-76.
35. Dwyer AA, Raivio T and Pitteloud N: Gonadotrophin replacement for induction of fertility in hypogonadal men. *Best Pract Res Clin Endocrinol Metab* 2015; 29(1): 91-03.
36. Rastrelli G, Corona G, Mannucci E and Maggi M: Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. *J Androl* 2014; 2(6): 794-08.
37. Schopohl J, Mehlretter G, Zumbusch R, Eversmann T and Werder K: Comparison of gonadotropin-releasing hormone and gonadotropin therapy in male patients with idiopathic hypothalamic hypogonadism. *Fertil Steril* 1991; 56(6): 1143-50.
38. Krausz C: Genetic Aspects of Male Infertility. *Eur Urol Rev* 2009; 3.
39. Santi D, Granata ARM and Simoni M: FSH treatment of male idiopathic infertility improves the pregnancy rate: a meta-analysis. *Endocr Connect* 2015; 4(3): 46-58.
40. Kumalic S and Pinter B: Review of clinical trials on effects of oral antioxidants on basic semen and other parameters in idiopathic oligoasthenoteratozoospermia. 2014 Article ID 426951, 11 pages.
41. Plouffe L and Siddhanti S: The effect of selective estrogen receptor modulators on parameters of the hypothalamic-pituitary-gonadal axis. *Ann N Y Acad Sci* 2001; 949: 251-58.
42. Somjen D, Katzburg S, Sharon O, Cohen M, Knoll E and Stern N: The effects of estrogen receptors  $\alpha$ - and  $\beta$ -specific agonists and antagonists on cell proliferation and energy metabolism in the human bone cell line. *J Cell Biochem* 2011; 112(2): 625-32.
43. Zhang B and Wu ZY: Estrogen derivatives: novel therapeutic agents for liver cirrhosis and portal hypertension. *Eur J Gastroenterol Hepatol* 2013; 25(3): 263-70.
44. Rossi V, Bellastella G, Rosa C, Abbondanza C, Visconti D and Maione L: Raloxifene induces cell death and inhibits proliferation through multiple signalling pathways in prostate cancer cells expressing different levels of estrogen receptor  $\alpha$  and  $\beta$ . *J Cell Physiol* 2011; 226(5): 1334-39.
45. Helguero LA, Faulds MH, Gustafsson JA and Haldosén LA: Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. *Oncogene* 2005; 24(44): 6605-16.
46. Hiraike OW, Imamov O, Hiraike H, Hultenby K, Schwend T and Omoto Y: Role of estrogen receptor  $\beta$  in colonic epithelium. *Proc Natl Acad Sci USA* 2006; 103 (8): 2959-64.
47. Hiraike OW, Hiraike H, Okinaga H, Imamov O, Rodrigo PA and Andrea M: Role of estrogen receptor  $\beta$  in uterine stroma and epithelium: Insights from estrogen receptor  $\beta$ -/- mice. *Proc Natl Acad Sci USA* 2006; 103 (48): 18350-55.
48. Clark JA, Alves S, Gundlach C, Rocha B, Birzin ET and Cai SJ: Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test. *Neuropharmacol* 2012; 63(6): 1051-63.
49. Buvat J, Ardaens K, Lemaire A, Gauthier A, Gasnault JP and Herbaut MB: Increased sperm count in 25 cases of idiopathic normogonadotropic oligospermia following



- treatment with tamoxifen. Fertil Steril 1983; 39 (5): 700-03.
50. Kotoulas IG, Cardamakis E, Michopoulos J, Mitropoulos D and Dounis A: Tamoxifen treatment in male infertility. I. Effect on spermatozoa. Fertil Steril 1994; 61(5): 911-4.
  51. Rowe PJ, Comhaire FH, Hargreave TB and Mellows HJ: WHO manual for the standardized Investigation and diagnosis of the infertile couple. Cambridge Univ press 2000; 37-60.
  52. Patankar SS, Kaore SB, Sawane MV, Mishra NV and Deshkar AM: Effect of clomiphene citrate on sperm density in male partners of infertile couples. Indian J Physiol Pharmacol 2007; 51(2): 195-8.
  53. Tang KF, Xing Y, Wu CY, Liu RZ, Wang XY and Xing JP: Tamoxifen combined with coenzyme Q10 for idiopathic oligoasthenospermia. Zhounghua Nan Ke Xue 2011; 17(7): 615-18.
  54. Santhi K and Sengottuvel R: Qualitative and Quantitative Phytochemical analysis of *Moringa concanensis* Nimmo. Int J of Curr Microbiol Appl Sci 2016; 5(1): 633-40.
  55. Ashokkumar P and Kanimozhi M: Phytochemical screening and antimicrobial activity from five Indian medicinal plants against human pathogens. Middle East J Sci Res 2010; 5(6): 477-82.
  56. Ukpo G, Ogbonna S, Ethaneta T and Bashir S: Immunostimulatory and Biochemical effects of Ethanolic extract of *Mangifera indica* stem bark on dexamethasone-induced immunosuppressed male rats. Int J pharm pharm Sci 2013; 5(2): 569-72.
  57. Sholikhah EN, Wijayanti MA, Nurani LH and Mustofa: Stage specificity of pasak bumi root (*Eurycoma longifolia* Jack) isolates on Plasmodium falciparum cycles. Med J Malaysia 2008; 63(1): 98-99.
  58. Tambi MI, Imran MK and Henkel RR: Standardized water-soluble extract of *Eurycoma longifolia*, Tongkat Ali, as testosterone booster for managing men with late-onset hypogonadism?. Andrologia 2012; 44(1): 226-20.
  59. Peiris LD, Dhanushka MA and Jayathilake TA: Evaluation of Aqueous Leaf extract of *Cardiospermum halicacabum* (L.) on Fertility of Male Rats. Biomed Res Int 2015; 175726.
  60. Bayatli F, Akkus D, Kilic E, Saraymen R and Sonmez MF: The protective effects of grape seed extract on MDA, AOPP, apoptosis and eNOS expression in testicular torsion: an experimental study. World J Urol 2013; 31(3): 615-622.
  61. Fakim A: Medicinal plants: traditions of yesterday and drugs of tomorrow, Mol Aspects Med 2006; 27(1): 1-93.
  62. Haseena S, Manjunath A, Kusal K and Saheb SH: Phytochemical Analysis of *Nigella sativa* and its Effect on Reproductive System. Int J Pharm Sci Res 2015; 7(8): 514-17.
  63. Luo Q, Li Z, Huang X, Yan J, Zhang S and Cai YZ: *Lycium barbarum* polysaccharides: Protective effects against heat-induced damage of rat testes and H2O2-induced DNA damage in mouse testicular cells and beneficial effect on sexual behaviour and reproductive function of hemicastrated rats. Life Sci 2006; 79(7): 613-21.
  64. Shalaby MA and Hammouda AA: Assessment of protective and antioxidant properties of *Tribulus terrestris* fruits against testicular toxicity in rats. J Intercult Ethnopharmacol 2014; 3(3): 113-18.
  65. Mohan VR, Balamurugan K and Shakthidevi G: Fertility Enhancement of *Polycarpaea corymbosa* L. (Lam) (Caryophyllaceae) whole plant on male Albino rats. Asian J Pharm Clin Res 2013; 6(5): 151-55.
  66. Chung HY, Noh Y, Kim MS, Jang A, Lee CE and Myung SC: Steroidogenic effects of *Taraxacum officinale* extract on the levels of steroidogenic enzymes in mouse Leydig cells. Anim Cell Syst 2018; 22(6): 407-14.
  67. Jahromi HK, Jashni HK and Dialeme S: Effect of damask rose extract on FSH, LH and testosterone hormones in rats. Int J Med ResHealth Sci 2016; 5(5): 267-71.

**How to cite this article:**

Sethumadhavan N: Causes, diagnosis and management of male infertility: phytocompounds as natural serms- a review. Int J Pharm Sci & Res 2022; 13(1): 130-38. doi: 10.13040/IJPSR.0975-8232.13(1). 130-38.

All © 2022 are reserved by the International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **Android OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)